Journal: The Journal of investigative dermatology
Article Title: The Regulation of Skin Fibrosis in Systemic Sclerosis by Extracellular ATP via P2Y 2 Purinergic Receptor.
doi: 10.1016/j.jid.2018.10.027
Figure Lengend Snippet: Figure 3. ATP-induced IL-6 production in SSc fibroblasts was mediated primarily via purinergic P2Y2 receptor. (a) IL-6 mRNA in SSc fibroblasts treated with ATP and/or nonselective P2 receptor antagonist suramin for 1 hour. (b) IL-6 mRNA in SSc fibroblasts treated with ATP and/or P2X4 receptor antagonist 5-BDBD, P2X7 receptor antagonist AZ11645373, P2Y1 receptor antagonist MRS2179, P2Y2 receptor antagonist AR-C118925XX, P2Y11 receptor antagonist NF157, P2Y12 receptor antagonist clopidogrel, and P2Y14 receptor antagonist PPTN for 1 hour. (c) IL-6 mRNA in SSc fibroblasts treated with ATP and/or P2Y2 receptor antagonist, kaempferol for 1 hour. n ¼ 3 patients. mRNA levels in fibroblasts without treatments were assigned a value of 1. All values represent mean standard error of the mean. *P < 0.05, **P < 0.01. ATP, adenosine triphosphate; SSc, systemic sclerosis.
Article Snippet: Cells were pretreated with the nonselective P2 receptor antagonist suramin (100 mmol/L; SigmaAldrich, St. Louis, MO), P2X4 receptor antagonist 5-BDBD (100 mmol/L; Tocris Bioscience, Bristol, UK), P2X7 receptor antagonist AZ11645373 (1 mmol/L; R&D Systems, Minneapolis, MN), P2Y1 receptor antagonist MRS2179 (100 mmol/L, Tocris Bioscience), P2Y2 receptor antagonists AR-C118925XX (10 mmol/L, Tocris Bioscience) and kaempferol (30 mmol/L, Sigma-Aldrich), P2Y11 receptor antagonist NF157 (50 mmol/L, Tocris Bioscience), P2Y12 receptor antagonist clopidogrel (30 mmol/L, Tokyo Chemical Industry, Tokyo, Japan), P2Y14 receptor antagonist PPTN hydrochloride (1 mmol/L, Tocris Bioscience), p38 inhibitor SB203580 (10 mmol/L, Wako), and BIRB796 (10 mmol/L; AdooQ Bioscience, Irvine, CA) for 30 minutes and then stimulated with 1 mmol/L ATP for 1 hour.
Techniques:
Tocris is a verified supplier 
Tocris manufactures this product 
